Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation

Bibliography

• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N
   PubMed Web of Science ®Google Scholar
• Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009;27:13-24, vii
   PubMedGoogle Scholar
• Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003;22:118-23
   PubMed Web of Science ®Google Scholar
• Lin HJ, Wolf PA, Kelly-Hayes M, Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Glazer NL, Dublin S, Smith NL, Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007;167:246-52
   PubMedGoogle Scholar
• Fuster V, Ryden LE, Cannom DS, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906
   PubMed Web of Science ®Google Scholar
• Hylek EM, Skates SJ, Sheehan MA, An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008;31:55-62
   PubMed Web of Science ®Google Scholar
• Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med 2006;48:182-9, 189 e1
   Google Scholar
• Bousser MG, Bouthier J, Buller HR, Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371:315-21
   PubMed Web of Science ®Google Scholar
• Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3-19
   PubMed Web of Science ®Google Scholar
• Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008;29:155-65
   PubMed Web of Science ®Google Scholar
• Albers GW. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 2004;10(14 Suppl):S462-9, discussion S469-73
   Google Scholar
• Hauel NH, Nar H, Priepke H, Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002;45:1757-66
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009
   Google Scholar
• Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004;64:577-95
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov 2008;7:557-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Pradaxa. 2008. Available from: http://www.emea. europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf [Last accessed 28 December 2009]
   Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155-62
   PubMed Web of Science ®Google Scholar
• Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008;68:1699-709
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Ahnfelt L, Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004;2:1573-80
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008;48:1411-19
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Limited Pradaxa. Summary of product characteristics. 2009. Available from: http://emc.medicines.org.uk/medicine/20760 [Last accessed 18 March 2010]
   Google Scholar
• Ezekowitz MD, Reilly PA, Nehmiz G, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Goldacre MJ, Roberts SE, Yeates D, Gill LE. Myocardial infarction: an investigation of measures of mortality, incidence and case-fatality. Report to the Department of Health. Oxford: National Centre for Health Outcomes Development; 2001
   Google Scholar
• Connolly S, Pogue J, Hart R, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12
   PubMed Web of Science ®Google Scholar
• RELY Trial Emergency Information. 2009. Available from: https:// www.rely-trial.com/RelyWeb/resources/jsp/emergency/intro.jsp [Last accessed 21 March 2010]
   Google Scholar